Pharmaceutical major Zydus Life shares continued their downward trajectory, dropping 0.18% to ₹1,106.7 during today's trading session, marking the fifth consecutive session of decline. According to Business Standard, the stock is trading at a PE ratio of 29.97 based on trailing twelve months earnings ending March 2026. Trading volume remained subdued at 3.8 lakh shares compared to the daily average of 13.4 lakh shares in the last month. The benchmark NIFTY Pharma index, to which Zydus Life belongs, is currently up 1.54% at 25,548.15 on the day, outperforming the broader market indices.
Pharmaceutical major Zydus Life has announced a final dividend of ₹1.00 per equity share for the financial year concluded on March 31, 2026. According to reports from Moneycontrol, the company's shares closed the previous trading session at ₹1,126.30, experiencing a 1.47% decline as investors processed the dividend announcement. The ex-date for this dividend has been fixed for July 24, 2026, making it a crucial cutoff for eligibility to receive the payout. The board of directors had formally approved this dividend proposal on May 19, 2026.
As reported by Moneycontrol, Zydus Life delivered robust financial performance for the year ending March 2026. The company posted a consolidated revenue of ₹27,148.40 crore, marking a substantial increase of approximately 16.8% compared to ₹23,241.50 crore in the previous fiscal year. The consolidated net profit also saw healthy growth, reaching ₹5,026.40 crore in March 2026, up about 8.9% from ₹4,614.80 crore in March 2025. Earnings Per Share (EPS) for the year stood at ₹50.09, demonstrating an increase of approximately 11.4% from ₹44.97 in the prior year. The company maintains a strong balance sheet with a Book Value Per Share (BVPS) of ₹269.50 as of March 2026.
According to Moneycontrol reports, Zydus Life also delivered strong quarterly results for the period ending March 2026. Consolidated revenue for this quarter was ₹7,587.00 crore, representing an approximate 10.5% increase from the ₹6,864.50 crore recorded in the December 2025 quarter. More notably, the consolidated net profit surged to ₹1,341.30 crore in the March 2026 quarter, a significant 39% jump compared to ₹965.10 crore in the preceding quarter. The quarterly EPS also showed strong growth, rising to ₹12.65 from ₹10.36 quarter-on-quarter. With a substantial market capitalization of approximately ₹1,13,332.13 crore, Zydus Life remains a key player in the Indian pharmaceutical industry.
Despite recent volatility, Zydus Life has demonstrated strong long-term performance, jumping 12.92% in the last one year compared to a 2.87% slide in NIFTY and a 13.98% spurt in the Nifty Pharma index. As per Business Standard, the stock has lost around 1.3% in the last one month, underperforming the broader pharma sector. The company's dividend yield of approximately 0.09% based on the current price of ₹1,106.7 may appear modest but reflects the company's stable profitability and positive indicator of management's confidence in sustained earnings within the resilient pharmaceutical sector. The company's Return on Equity (ROE) remained healthy at 18.58%, reflecting efficient utilization of shareholder funds, while the Debt to Equity ratio increased to 0.43 in March 2026 from 0.13 in March 2025.
